TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02210715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress.
Description: 28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continue usual antiretroviral therapy
Description: 28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
Study: NCT02015000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: P.E.R.F.A.M.T
Description: Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
Study: NCT01674530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 mcg capsules of both experimental Lubiprostone and AMITIZA
Study: NCT00699322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg P.O. per day for 1month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 2mg P.O. per day for 1 month
Study: NCT04332302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power resistance training
Description: Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
Study: NCT00322491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study: NCT02236715

Intervention type: DRUG
Intervention: Atrovent®
Study: NCT01924130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classroom feeding
Description: Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education lessons
Description: Students receive breakfast specific nutrition education lessons.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Marketing
Description: A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent outreach
Description: A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
Study: NCT03627936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin manufactured at Zofingen
Description: Lorcaserin XR tablets manufactured at Zofingen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin manufactured at Zofingen
Description: Lorcaserin XR tablets manufactured at Zofingen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin manufactured at Kawashima
Description: Lorcaserin XR tablets manufactured at Kawashima.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin manufactured at Kawashima
Description: Lorcaserin XR tablets manufactured at Kawashima.
Study: NCT02401282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: This is a modification of the dot-probe task (placebo task) designed to train attention away from threat

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dot-probe task
Description: This is the active control placebo condition that simply measures levels of attention to threat
Study: NCT04053790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactobacillus LB
Description: administration of different doses of Lactobacillus LB according to the treatment groups described previously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactobacillus LB
Description: administration of different doses of Lactobacillus LB according to the treatment groups described previously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a tablet of placebo every 12 hours given by mouth
Study: NCT01933607

Intervention type: DEVICE
Group type: OTHER
Intervention: TOPS System
Description: Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
Study: NCT02952495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online alcohol educational class
Description: Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care.
Study: NCT00399581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Frequency Oscillatory Ventilation-Hi
Description: HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Frequency Oscillatory Ventilation-Lo
Description: HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
Study: NCT02068040

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CocoaVia
Description: CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
Study: NCT04289636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss program
Description: Using a combination of individual (\~1x/month) and group-based (\~3x/month) meetings, participants will be taught behavioral approaches for changing diet and exercise behaviors. This intervention will be 15 weeks in duration and will be delivered remotely using a video-conferencing platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program
Description: Using a combination of individual (\~1x/month) and group-based (\~3x/month) meetings, participants will be taught behavioral approaches for changing diet and exercise behaviors. This intervention will be 15 weeks in duration and will be delivered remotely using a video-conferencing platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion
Description: This 8-week, group-based program will help train individuals on how to handle difficult emotions with greater ease, how to transform difficult relationships, and how to motivate and encourage oneself, rather than being self-critical.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and cooking education
Description: This 8-week, group-based program will help individuals to improve the quality of their diet through nutrition education and basic cooking skills for preparing healthy meals.
Study: NCT00680121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benfotiamine
Description: Benfotiamine 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03305029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCNT-hES-RPE Cells
Description: Pars Plana Vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial(SCNT-hES-RPE) Cells in Patients with Advanced Dry Age-related Macular Degeneration
Study: NCT01282151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
Study: NCT06486324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)
Description: asymmetric maxillary expansion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)
Description: asymmetric maxillary expansion
Study: NCT01683175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis-platinum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Study: NCT01263158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expectancy of standard oxytocin treatment
Study: NCT00472290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim (formerly AMG 531)
Description: Subjects will begin the study at an initial dose of 750 µg.~Except for:~* Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~* Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count.
Study: NCT04428541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire for visual function assessment of preverbal children
Description: 18 items questionnaire
Study: NCT01434836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS and working memory training
Description: This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS and working memory training
Description: This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
Study: NCT01205607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR -5 mm Hg then -9 mm Hg
Description: the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR -9 & then -5mm Hg
Description: the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
Study: NCT01431924

Intervention type: DRUG
Intervention: Higher-dose inhaled corticosteroids
Description: fluticasone propionate 110 or 220 mcg

Intervention type: DRUG
Intervention: Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination
Description: Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
Study: NCT04088214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic lateral soft tissue release
Description: The arthroscopic lateral soft tissue release is performed using an inside-out approach via the 1MTPJ arthroscopy.
Study: NCT03876613

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Different music types
Description: the type of music that reduces anxiety best and most effectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Different music types
Description: the type of music that reduces anxiety best and most effectively.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Different music types
Description: the type of music that reduces anxiety best and most effectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Different music types
Description: the type of music that reduces anxiety best and most effectively.
Study: NCT02090608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol was administered at the dose of 1 mcg/die
Study: NCT03106584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aquamin-Plus
Description: Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg~Dosage:~4 Capsules is equal to effective dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aquamin-Plus
Description: Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg~Dosage:~4 Capsules is equal to effective dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Description: The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).~Dosage:~4 Capsules is equal to effective dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine sulphate
Description: The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).~Dosage:~4 Capsules is equal to effective dose
Study: NCT02193438

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spices intake
Description: Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tomato juice intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tomato juice intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tomato juice intake
Study: NCT03342495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: Social worker/Patient Navigator will be assigned to follow youth in adult care for up to 24 months to assist youth adapt and attach to adult delivered healthcare

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Whatever processes are in place in a variety of clinics to support transfer from pediatric to adult care in the pediatric clinics
Study: NCT01439165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and Diphtheria Toxoids Adsorbed For Adult Use
Description: 0.5 mL, Intramuscular
Study: NCT00891475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation; Interferon-alpha
Description: Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation; Sunitinib maleate
Description: Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib maleate
Description: 38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
Study: NCT04860492

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Renalof 325mg
Description: RENALOF® is a preparation that contains active Agropyron repens extract. It is designed with specific antioxidant compounds triggered by a bio-catalyst process that enables improved control of the production mechanism of anti-stress molecules. RENALOF® contains extracts of couch grass (triticin, potassium salts, agropyron, silicic salt, inositol, vanillin, saponin, mucilage, iron, and others trace elements), mannitol, corn starch and magnesium silicate. The magnesium in RENALOF® inhibits stone formation by inhibition of growth of crystals and aggregation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Renalof 325mg
Description: RENALOF® is a preparation that contains active Agropyron repens extract. It is designed with specific antioxidant compounds triggered by a bio-catalyst process that enables improved control of the production mechanism of anti-stress molecules. RENALOF® contains extracts of couch grass (triticin, potassium salts, agropyron, silicic salt, inositol, vanillin, saponin, mucilage, iron, and others trace elements), mannitol, corn starch and magnesium silicate. The magnesium in RENALOF® inhibits stone formation by inhibition of growth of crystals and aggregation.
Study: NCT00796900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
Study: NCT00067236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-116800 (given as PG-530742)
Description: 200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: placebo tablet, twice a day for 90 days
Study: NCT03843203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - tDCS
Description: - Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - tDCS
Description: - Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - tDCS
Description: - Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
Study: NCT00726700

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV